RZLT Stock Overview
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rezolute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.30 |
| 52 Week High | US$3.63 |
| 52 Week Low | US$0.72 |
| Beta | 1.32 |
| 1 Month Change | 73.68% |
| 3 Month Change | 230.03% |
| 1 Year Change | 69.23% |
| 3 Year Change | -47.70% |
| 5 Year Change | -63.33% |
| Change since IPO | -99.50% |
Recent News & Updates
Recent updates
Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate
Feb 13
Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price
Sep 21Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation
Jul 25We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth
Jan 31Rezolute GAAP EPS of -$0.37
Sep 15We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate
May 06Rezolute shares rise on positive topline results from RZ402 eye disease trial
May 04What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?
Jan 12Shareholder Returns
| RZLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 26.9% | -4.7% | -3.7% |
| 1Y | 69.2% | -2.7% | 20.2% |
Return vs Industry: RZLT exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: RZLT exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| RZLT volatility | |
|---|---|
| RZLT Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RZLT's share price has been volatile over the past 3 months.
Volatility Over Time: RZLT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 57 | Nevan Elam | www.rezolutebio.com |
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.
Rezolute, Inc. Fundamentals Summary
| RZLT fundamental statistics | |
|---|---|
| Market cap | US$132.42m |
| Earnings (TTM) | -US$56.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs RZLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RZLT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$56.83m |
| Earnings | -US$56.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RZLT perform over the long term?
See historical performance and comparison